NASDAQ: ROIV · Life Sciences · 11 alerts · CIK 1635088
Share price
$38.61Close, Nov 16
Market cap
$28B
Shares outstanding
724.56MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Roivant Sciences Ltd. filings on SEC EDGAR ↗
Roivant Sciences Ltd. reported 724,561,460 common shares outstanding as of November 3, 2026. The filing includes condensed consolidated financial statements for the three and six months ended September 30, 2026, and highlights risks related to biopharmaceutical product development, capital allocation, and its 'Vant' structure.
Roivant Sciences reported financial results for its second fiscal quarter ended September 30, 2026, highlighted by $31.0 million in net product revenue from the first five weeks of the LISRAYA launch. The company also announced positive clinical data for IMVT-1402 in rheumatoid arthritis and brepocitinib in non-infectious uveitis, ending the period with $4.2 billion in cash and marketable securities.
Term
Q2 2026
“This quarter has marked a major transition for Roivant. LISRAYA is now commercially available to patients and we are off to a strong start, with $31.0 million in net product revenue in the first 5 weeks of launch – reflecting strong early patient and prescriber demand.”
Matt Gline, CEO of Roivant
“Today we are thrilled to announce that IMVT-1402 succeeded in Immunovant’s study in difficult-to-treat late line rheumatoid arthritis – IMVT-1402 at the 600 mg dose met the primary endpoint in Period 2, and the broader data support its potential to maintain and deepen responses in patients who have failed multiple advanced therapies and who are in need of new options.”